Literature DB >> 10579437

Antimeningococcal herd immunity in the Czech Republic--influence of an emerging clone, Neisseria meningitidis ET-15/37.

P Kriz1, B Kriz, E Svandova, M Musilek.   

Abstract

For many years, invasive meningococcal disease in the Czech Republic occurred sporadically and was caused mainly by meningococci of serogroup B. In 1993, when a new clone (ET-15/37) emerged, the only phenotype found was C:2a:P1.2,5. In 1995, an antigenic variation of the ET-15/37 clone, B:2a:P1.2,5, occurred. The results of immunological surveys conducted in 1989 and 1996 were compared. A significantly higher proportion of 1996 sera than those collected in 1989 showed bactericidal antibodies against N. meningitidis B:2a:P1.2,5 (19.7 vs. 5.1%) and N. meningitidis C:2a:P1.2,5 (15.9 vs. 7.4%), consistent with increased herd immunity due to the spread of the new clone in the Czech Republic. There were differences in the age distribution of the positive sera.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579437      PMCID: PMC2810749          DOI: 10.1017/s095026889900285x

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  11 in total

1.  Detection of meningococcal carriage by culture and PCR of throat swabs and mouth gargles.

Authors:  J Zoe Jordens; Jeannette N Williams; Graeme R Jones; John E Heckels
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

Review 2.  Invasive meningococcal disease in the 21st century—an update for the clinician.

Authors:  Rachel Dwilow; Sergio Fanella
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

Review 3.  An epidemiological review of changes in meningococcal biology during the last 100 years.

Authors:  Anne Abio; Keith R Neal; Charles R Beck
Journal:  Pathog Glob Health       Date:  2013-12-19       Impact factor: 2.894

4.  Standardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assay.

Authors:  Tamara Rodríguez; Miriam Lastre; Barbara Cedré; Judith del Campo; Gustavo Bracho; Caridad Zayas; Carlos Taboada; Miriam Díaz; Gustavo Sierra; Oliver Pérez
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

5.  Phenotypic and genotypic approaches to characterization of isolates of Neisseria meningitidis from patients and their close family contacts.

Authors:  G Tzanakaki; R Urwin; M Musilek; P Kriz; J Kremastinou; A Pangalis; C C Blackwell; M C Maiden
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

6.  Epidemiology of meningococcal disease in Switzerland, 1999-2002.

Authors:  H Jaccard Ruedin; B Ninet; E Pagano; P Rohner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-22       Impact factor: 3.267

7.  Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.

Authors:  Chiara de Waure; Alessandro Miglietta; Darko Nedovic; Giovanna Mereu; Walter Ricciardi
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

8.  The seroepidemiology of herpes simplex virus type 1 and 2 in Europe.

Authors:  R G Pebody; N Andrews; D Brown; R Gopal; H De Melker; G François; N Gatcheva; W Hellenbrand; S Jokinen; I Klavs; M Kojouharova; T Kortbeek; B Kriz; K Prosenc; K Roubalova; P Teocharov; W Thierfelder; M Valle; P Van Damme; R Vranckx
Journal:  Sex Transm Infect       Date:  2004-06       Impact factor: 3.519

9.  Effect of mesoporous silica under Neisseria meningitidis transformation process: environmental effects under meningococci transformation.

Authors:  Luciana M Hollanda; Gisele Cg Cury; Rafaella Fc Pereira; Gracielle A Ferreira; Andreza Sousa; Edesia Mb Sousa; Marcelo Lancellotti
Journal:  J Nanobiotechnology       Date:  2011-07-25       Impact factor: 10.435

10.  Serogroup C meningococci in Italy in the era of conjugate menC vaccination.

Authors:  Paola Stefanelli; Cecilia Fazio; Tonino Sofia; Arianna Neri; Paola Mastrantonio
Journal:  BMC Infect Dis       Date:  2009-08-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.